Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine

¹ Belgorod State National Research University Belgorod, Russia
² Dept. of Social Pharmacy, National University of Pharmacy, Kharkiv, Ukraine
³ Dept. of Pharmaceutical Marketing and Management National University of Pharmacy, Kharkiv, Ukraine

^* Corresponding author: bezuglaya@bsu.edu.ru

Abstract

A pharmacoeconomic study of the rationality of the use of various chemotherapy regimens (“7 + 3” scheme) in the treatment of patients with acute forms of myeloid leukemia has been carried out. The use of the chemotherapy regimen “7 + 3” with 200 mg / m² / per day dosage of cytarabine on 1-7 days allows to achieve a unit of treatment efficacy at a lower cost (CEA = 19.22 US $ / per unit of efficacy), compared with another dosage of cytarabine that was two times less, i.e., 100 mg / m² / day at the same period (CEA = US $ 20.18 / unit of effectiveness). The presented research results can be used in the formation of programs for the rational use of limited resources in the purchase of anticancer drugs for hematological cancer patients, as well as in the development of schemes for providing them with effective medical care in a hospital setting.